(FCET)
The Frankfurt Center for Emerging Therapeutics (FCET) brings together cutting-edge technology platforms for advanced biomedical research and the development of new therapies. Located at the Riedberg and Niederrad campuses, FCET connects expertise in medicinal chemistry, RNA and protein research, biophysics, cellular analysis, proteomics, genomics, and computational biomedicine to foster interdisciplinary collaboration.
The following subsections represent the different areas of FCET. For more information and specific contacts, click the respective button.
Image-based live-cell screening with modified cell lines and fluorescent reporters enables siRNA and compound treatments and dye-based analyses. Automated liquid handling supports the analysis of BSL-1 cells.
Complex human 3D in vitro models of the intestine, lung, skin, and blood-brain barrier enable studies of permeability, biocompatibility, and immunogenicity under physiological and pathophysiological conditions.
Protein production in E. coli, insect, or mammalian cells includes expression, extraction, purification, validation, and assessment of protein homogeneity, with optional functional assays and crystallization.
Gene perturbation using genome-wide or tailored CRISPR-Cas9 libraries enables quantitative phenotypic profiling to identify essential genes, synergistic effects, novel pathways, and complex components.
Proteomics is a powerful method for evaluating drug-protein interactions. It is based on evaluating the quantity of thousands of cellular proteins that are produced upon treatment with chemicals.
Computational approaches integrate genomics, proteomics, and structural biology data with advanced algorithms and simulations to identify drug targets, predict interactions, and optimize therapeutic candidates.
DARPins and Sybodies are small, stable proteins that can be selected as high-affinity binders for specific targets. Selection experiments enable their use in molecular research and intracellular applications.
Medicinal chemistry services include the design, synthesis, optimization, and validation of small-molecule inhibitors and PROTACs, including library screening, binding assays, and cellular target validation.
Director: Prof. Dr. Christian Münch
Vice Director: Dr. Alexandra Stolz
Dr. Anne-Claire Jacomin
FCET Management Office
Phone: +49 (0)69 798 42510
Email: FCET@uni-frankfurt.de
